Blue Horizon International does not offer or provide medical treatment or see patients within the United States. Our cellular and exosome products are investigational and are not approved by the U.S. FDA. This website is for informational and educational purposes only and is not medical advice.

Style Sampler

Layout Style

Patterns for Boxed Mode

Backgrounds for Boxed Mode

All fields are required.

Close Appointment form

Brian Mehling, MD slated to participate in the 19th Annual World Congress of Society for Brain Mapping and Therapeutics

  • Home
  • Brian Mehling, MD slated to participate in the 19th Annual World Congress of Society for Brain Mapping and Therapeutics
Brian Mehling, MD slated to participate in the 19th Annual World Congress of Society for Brain Mapping and Therapeutics

No Comments

Breaking Boundaries of Science, Technology, Medicine, Art, and Healthcare Policy meeting being held in LA March 10-13

Brian Mehling, MD, founder and chief medical officer of BHI Therapeutic Sciences, will virtually present on three topics at the 19th Annual World Congress of Society for Brain Mapping and Therapeutics. The meeting, entitled Breaking Boundaries of Science, Technology, Medicine, Art, and Healthcare Policy, will be held at the Los Angeles Convention Center, March 10-13.


Dr. Mehling will speak on the following: Safety study of Cultured Wharton’s Jelly Mesenchymal Stem Cells, Umbilical cord-derived stem cell therapy for multiple sclerosis treatment – a single subject case study, and Mesenchymal stem cell therapy for drowning induced hypoxic brain injury – A pediatric case report study of recovery.

Dr. Mehling is a board-certified American orthopedic trauma surgeon, researcher, and philanthropist. He is spearheading groundbreaking research in stem cell therapy focused on treatment and research using stem cells. He is also board-certified in anti-aging and regenerative medicine.
“We are focused on bringing advanced stem cell therapies within reach of a wider audience, “said Dr. Mehling. We envision a future in which stem cells are preferred over many surgical, pharmacological, and rehabilitative medical services,” he added. He and his colleagues are conducting clinical investigations to evaluate the safety and efficacy of adult stem cells in therapy of chronic inflammation, musculoskeletal conditions, stroke, spinal cord injury and other medical conditions.


This program is jointly Sponsored by Johns Hopkins University School of Medicine and Saint Louis University School of Medicine for Continuing Medical Education (CME) including 700+ presentations (live and virtual),13 keynotes, three panel discussions, and two bio-skills labs (Brain and Spine).

BHI Therapeutic Sciences (BHITS) supports investigational research and education in stem cell and regenerative medicine using ethically sourced cord blood cells.


Media Contact
Doreen Santora 201-342-7662
dsantora@bluehorizoninternational.com

  • Share This

About the author

Related Posts

Submit a comment

Your email address will not be published. Required fields are marked *

Leave a Reply

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>